^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TSC-200-A0201
i
Other names: TSC-200-A0201, TSC-200-A2, TSC-200, TCR-200-A02, TSC-200-A02
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TSCan Therap
Drug class:
TCR modulator, HPV-16 E7 protein inhibitor
Related drugs:
10ms
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=100, Recruiting, TScan Therapeutics, Inc. | Initiation date: Nov 2023 --> Feb 2024
Trial initiation date • IO biomarker • Pan tumor • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*02
|
T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
1year
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=100, Recruiting, TScan Therapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Pan tumor • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*02
|
T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
over1year
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=100, Not yet recruiting, TScan Therapeutics, Inc.
New P1 trial • Pan tumor • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*02
|
T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
Share via
